Analysts Anticipate Bausch Health Companies Inc. (NYSE:BHC) Will Post Earnings of $1.09 Per Share

Equities analysts predict that Bausch Health Companies Inc. (NYSE:BHC) will report $1.09 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Bausch Health Companies’ earnings, with the highest EPS estimate coming in at $1.19 and the lowest estimate coming in at $0.98. Bausch Health Companies posted earnings per share of $1.33 during the same quarter last year, which would suggest a negative year-over-year growth rate of 18%. The company is expected to announce its next quarterly earnings report on Wednesday, February 23rd.

According to Zacks, analysts expect that Bausch Health Companies will report full-year earnings of $4.23 per share for the current year, with EPS estimates ranging from $4.11 to $4.32. For the next year, analysts anticipate that the firm will report earnings of $4.73 per share, with EPS estimates ranging from $4.11 to $5.05. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Tuesday, November 2nd. The company reported $1.14 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.07 by $0.07. Bausch Health Companies had a negative net margin of 13.85% and a negative return on equity of 2,440.75%. The company had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.15 billion.

Several research analysts have recently commented on BHC shares. Barclays dropped their price target on shares of Bausch Health Companies from $35.00 to $31.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 4th. Royal Bank of Canada dropped their price target on shares of Bausch Health Companies from $41.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 3rd. BMO Capital Markets reiterated a “hold” rating on shares of Bausch Health Companies in a research note on Monday, November 8th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Bausch Health Companies in a research note on Friday, October 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $36.22.

Shares of BHC traded up $0.08 during mid-day trading on Thursday, hitting $26.11. 1,280,183 shares of the company’s stock were exchanged, compared to its average volume of 3,088,960. The firm has a fifty day moving average of $27.66 and a two-hundred day moving average of $28.69. Bausch Health Companies has a twelve month low of $18.49 and a twelve month high of $34.80. The stock has a market cap of $9.37 billion, a price-to-earnings ratio of -7.96, a P/E/G ratio of 1.45 and a beta of 1.56.

A number of hedge funds and other institutional investors have recently bought and sold shares of BHC. Price T Rowe Associates Inc. MD grew its position in Bausch Health Companies by 48.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 7,850,573 shares of the company’s stock worth $230,179,000 after purchasing an additional 2,553,297 shares during the last quarter. ING Groep NV bought a new position in shares of Bausch Health Companies during the 3rd quarter worth about $55,700,000. Factorial Partners LLC lifted its holdings in shares of Bausch Health Companies by 2,553.7% during the 1st quarter. Factorial Partners LLC now owns 1,618,740 shares of the company’s stock worth $51,000,000 after acquiring an additional 1,557,740 shares during the period. Fir Tree Capital Management LP bought a new position in shares of Bausch Health Companies during the 2nd quarter worth about $45,554,000. Finally, Letko Brosseau & Associates Inc. bought a new position in shares of Bausch Health Companies during the 3rd quarter worth about $32,458,000. Institutional investors own 75.43% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.

Featured Article: Why is cost of goods sold important?

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.